A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer
Study Details
Study Description
Brief Summary
This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer. At least 30 subjects will be recruited in this study. The subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2 by an intravenous infusion (IV), every 21 days (q3w, 1 cycle). All patients will receive the treatment until disease progression, intolerable toxic reaction, death, or withdrawal by investigator or patient decision (a maximum of 8 cycles). Delays in drug administration is allowed from the cycle 2, however, the delays should be no more than 3 weeks. Dose adjustments after the cycle 2 is permitted, and the minimum dose is 12mg/m2.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Mitoxantrone Hydrochloride Liposome Injection Subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles. |
Drug: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
|
Outcome Measures
Primary Outcome Measures
- adverse events (AEs) [from the initiation of the first dose to 28 days after the last dose，assessed up to 36 months]
The incidence and severity of AEs, abnormalities in physical exams, vital sign assessments, clinical laboratory assessments, ultrasonic cardiograms (UCGs) and electrocardiographs (ECGs).
Secondary Outcome Measures
- overall response rate (ORR) [From the enrollment to the final documentation of response of the last subject (assessed up to 36 months)]
To investigate the preliminary antitumor efficacy
- duration of response (DoR) [From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months]
To investigate the preliminary antitumor efficacy
- duration of complete response (DCR) [From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months]
To investigate the preliminary antitumor efficacy
- progression-free survival (PFS) [From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months]
To investigate the preliminary antitumor efficacy
- overall survival (OS) [From the enrollment to the death of last subject or the end of the clinical trial (assessed up to 36 months)]
To investigate the preliminary antitumor efficacy
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subjects fully understand and voluntarily participate in this study and sign informed consent;
-
Age ≥18, female;
-
Histologically confirmed diagnosis of epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma (excluding low grade serous carcinoma and mucous carcinoma);
-
Fail to respond to or progressed on the standard platinum-based therapy ;
-
At least one measurable lesion according to RECIST v1.1;
-
ECOG performance status of 0 to 2;
-
Life expectancy ≥ 12 weeks;
-
AEs from the previous treatment have resolved to ≤ Grade 1 based on CTCAE (except for the toxicity without safety risk judged by the investigator, such as hair loss, hyperpigmentation);
-
Adequate organ function;
-
Subjects of childbearing potential must agree to use effective contraceptive measures. Female subjects must have a negative pregnancy test before enrolment;
-
Fully comply with the protocol.
Exclusion Criteria:
-
History of allergy to mitoxantrone hydrochloride or any excipients of the study drug;
-
Untreated or symptomatic central nervous system (CNS) metastases;
-
Pericardial effusion with clinical symptoms
-
History of allotransplantation;
-
Known hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or other active viral infection;
-
Serious infection or interstitial pneumonia within 1 week prior to the first dose administration;
-
Use of other anticancer treatment within 4 weeks prior to the first dose administration;
-
Enrolled in any other clinical trials within 4 weeks prior to the first dose administration;
-
Major surgery within 3 months prior to the first dose administration, or have a surgical schedule during the study period;
-
Thrombosis or thromboembolism within 6 months prior to screening;
-
History of, or known additional malignant tumor within 3 years, except for tumors have been cured and have not recurred, and carcinoma in situ;
-
Impaired cardiac function or serious cardiac disease;
-
Previous treatment with adriamycin or other anthracyclines, and the total cumulative dose of prior adriamycin or equivalent is >350 mg/m2.
-
Pregnant or lactating female;
-
Serious and/or uncontrolled systemic diseases;
-
Not suitable for this study as decided by the investigator due to other reasons.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Chongqing University Cancer Hospital | Chongqing | Chongqing | China | 400030 |
| 2 | Fujian Cancer Hospital | Fuzhou | Fujian | China | 350014 |
| 3 | Guangxi Medical University Cancer Hospital | Nanning | Guangxi | China | 530021 |
| 4 | Guizhou Cancer Hospital | Guiyang | Guizhou | China | 550000 |
| 5 | Harbin Medical University Hospital | Harbin | Heilongjiang | China | 150081 |
| 6 | Henan Cancer Hospital | Zhengzhou | Henan | China | 450000 |
| 7 | Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology | Wuhan | Hubei | China | 430022 |
Sponsors and Collaborators
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Investigators
- Principal Investigator: Qi Zhou, Master, Chongqing University Cancer Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HE071-CSP-015